Lipid-engineered antibody-based therapeutics target inflamed joints and lymph nodes to enhance rheumatoid arthritis treatment.
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation and joint damage. Although antibody (Ab)-based biologic disease-modifying anti-rheumatic drugs (bDMARDs) have transformed RA treatment, their efficacy remains limited in many patients. Here, we conjugate Ab-based bDMARDs wi...